ILSUNG IS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19,600 KRW | -0.56% |
|
-0.96% | -17.12% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 61.25B 45.14M 61.49M | Sales 2023 | 78.05B 57.53M 78.37M | Capitalization | 165B 121M 165M |
|---|---|---|---|---|---|
| Net income 2022 | 105B 77.56M 106M | Net income 2023 | -20.94B -15.43M -21.02M | EV / Sales 2022 | -2.85 x |
| Net cash position 2022 | 300B 221M 301M | Net cash position 2023 | 235B 173M 236M | EV / Sales 2023 | -0.9 x |
| P/E ratio 2022 |
1.2
x | P/E ratio 2023 |
-7.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 3.99% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.56% | ||
| 1 week | -0.96% | ||
| Current month | -1.51% | ||
| 1 month | +0.98% | ||
| 3 months | -17.12% | ||
| 6 months | -3.92% | ||
| Current year | -17.12% |
1 week
19 410.00
19 970.00
1 month
18 310.0020 450.00
Current year
18 310.0025 650.00
1 year
18 310.0029 000.00
3 years
13 780.0038 000.00
5 years
13 780.0038 000.00
10 years
13 780.0038 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Wook Yoon
CEO | Chief Executive Officer | 38 | - |
Suk-Keun Yoon
CEO | Chief Executive Officer | 68 | - |
Hye-Suk Na
BRD | Director/Board Member | 57 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Suk-Keun Yoon
CEO | Chief Executive Officer | 68 | - |
Duk-Keun Yoon
PRN | Corporate Officer/Principal | 64 | - |
Jong-Ho Yoon
BRD | Director/Board Member | 41 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 19,600 | -0.56% | 6,500 |
| 24-05-14 | 19,710 | -0.05% | 12,127 |
| 24-05-13 | 19,720 | -0.55% | 3,408 |
| 24-05-10 | 19,830 | +0.20% | 5,382 |
| 24-05-09 | 19,790 | -0.25% | 5,713 |
End-of-day quote Korea S.E., May 15, 2024
More quotes
Ilsung IS Co Ltd, formerly Ilsung Pharmaceutical Co Ltd, is a Korea-based company mainly engaged in the pharmaceuticals manufacture and sale business. The Companyâs products consist of penicillin antibiotics, contrast mediums, digestive drugs, cardiovascular agents, antihistamines, anti-diabetics, bone disease drugs, analgesics, muscle relaxants, anesthetics, skin disease drugs, cardiovascular drugs, psychiatry drugs, antivirals, antipyretics and others. The Company distributes its products through wholesalers, hospitals, pharmacies and others. The Company also provides consignment production services.
Sector
Pharmaceuticals
Calendar
2024-11-12
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.12% | 101M | |
| +21.72% | 44.15B | |
| +23.05% | 23.02B | |
| +19.25% | 15.33B | |
| +12.88% | 13.74B | |
| +49.88% | 12.16B | |
| -10.31% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.88% | 5.66B |
- Stock Market
- Equities
- A003120 Stock
